{"id":"dichlorphenamide-open-label","safety":{"commonSideEffects":[{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Altered taste"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Metabolic acidosis"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":{"chemblId":"CHEMBL17","moleculeType":"Small molecule","molecularWeight":"305.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dichlorphenamide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor in the eye by inhibiting the enzyme carbonic anhydrase in the ciliary body. This reduction in aqueous humor production leads to lower intraocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management. It is a topical or systemic agent used to prevent vision loss associated with elevated intraocular pressure.","oneSentence":"Dichlorphenamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:22.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary angle-closure glaucoma or ocular hypertension (Phase 3 trial context)"}]},"trialDetails":[{"nctId":"NCT00494507","phase":"PHASE3","title":"Hyper- and Hypokalemic Periodic Paralysis Study","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-06","conditions":"Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daranide"],"phase":"phase_3","status":"active","brandName":"Dichlorphenamide (open-label)","genericName":"Dichlorphenamide (open-label)","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dichlorphenamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure. Used for Primary angle-closure glaucoma or ocular hypertension (Phase 3 trial context).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}